HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), PDL1 inhibitors(Programmed death-ligand 1 inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors)

Therapeutic Areas

NeoplasmsRespiratory Diseases

Active Indication

Advanced Lung Non-Small Cell CarcinomaMetastatic Solid TumorHER2 Positive Solid Tumors+ [1]

Inactive Indication

Gastrointestinal Neoplasms

Originator Organization

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Active Organization

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC38H43N9O8

InChIKeyQODRVHFOPFCZOM-IUDBTDONSA-N

CAS Registry-

Boost your research with our ADC technology data.

view full example data

Sequence Code 18481L

The sequence is quoted from: *****

Sequence Code 315610456H

The sequence is quoted from: *****

Sequence Code 525560003H

The sequence is quoted from: *****

Sequence Code 525560004H

The sequence is quoted from: *****

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Lung Non-Small Cell Carcinoma	Phase 2	China	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	23 Sep 2025
HER2 Positive Solid Tumors	Phase 2	Australia	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	26 Mar 2024
Gastrointestinal Neoplasms	Phase 2	Australia	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	18 Jan 2024
Metastatic Solid Tumor	Phase 2	Australia	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	18 Jan 2024
Non-Small Cell Lung Cancer	Phase 2	Australia	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	18 Jan 2024
Advanced cancer	Phase 1	China	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	08 Jan 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06226766 (JSKN033-101, SITC2024) Manual	Phase 1/2	Advanced Malignant Solid Neoplasm	10	JSKN033	tgttpqllju(pfgjwcdbxx) = The most common was mild to moderate injection site reactions (Grade 1–2). lntszyfvwq (mqdztdtein ) View more	Positive	05 Nov 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis